New York, NY—May 5, 2005
Research and advances in clinical practice are increasingly demonstrating that a narrow "window of opportunity" to slow down or potentially halt joint damage caused by rheumatoid arthritis (RA) may exist in the early stages of the disease, according to doctors at Hospital for Special Surgery (HSS).
"There is a therapeutic window of opportunity to prevent joint damage in RA, and that window opens early," said Theodore Fields, MD, a rheumatologist and clinical director of Hospital for Special Surgery’s Gosden Robinson Early Arthritis Center (EAC). "We have treatments available today that can put the brakes on the progression of rheumatoid arthritis. But the real key is avoiding delay in treatment."
Many RA patients do not seek medical help because they erroneously assume nothing can be done for arthritis. Others may experience delayed therapy because their primary care physicians don't realize or accept the treatment advances that have resulted from rheumatology research in the last ten years. Doctors at Hospital for Special Surgery’s Early Arthritis Center stress that RA often begins with inflammation in a few joints. Once that pain persists for three or more months it is unlikely to go away on its own and often spreads to multiple other joints.
"Waiting too long to be evaluated and treated by a rheumatologist can result in unnecessary joint destruction. We’ve developed a group of early warning signs patients can use to determine if they need to see a rheumatologist," Dr. Fields added.
HSS offers the following six warning signs of RA to help patients determine if they should visit a rheumatologist:
According to the Arthritis Foundation, a co-sponsor of National Arthritis Month in May, rheumatoid arthritis afflicts one percent of the U.S. population (2.1 million Americans). Three fourths of these RA sufferers, about 1.5 million, are estimated to be women.
Treatment of RA that focuses only on pain relief, and not joint damage prevention, often leads to poor long-term results. However, when RA is treated within the first three to six months after symptoms are first noticed, research has shown that patients experience improved outcomes. A study by a Dutch research group demonstrated that patients who received early treatment of recent-onset RA experienced less joint deterioration at two years after diagnosis than those who received later treatment (1). Early treatment can include:
Rheumatologists look at a number of factors to try to predict the long-term risk of joint damage, including:
Over 100 kinds of arthritis exist, making it important that inflammatory-type arthritis – with RA being the most common type of inflammatory arthritis – be quickly identified. It is important to separate inflammatory arthritis from degenerative arthritis like osteoarthritis – a degenerative "wear and tear" joint disease that is the leading cause of disability in the United States – since treatment is completely different. Osteoarthritis ends to affect people over 50 and increases with age, while inflammatory arthritis such as RA has its most common onset between the ages of 30 and 50. Since RA commonly affects people in their child-bearing and peak-earning years, the disability can be costly for both patients and society. According to the Arthritis Foundation, fewer than 50 percent of working age adults with RA are still employed ten years after disease onset. The best hope for improved outcomes for individuals with RA is early diagnosis and treatment.
About the Gosden Robinson Early Arthritis Center
The Gosden Robinson Early Arthritis Center (EAC) was founded to promote the early diagnosis and treatment of arthritis and to support research efforts to determine more effective treatment and prevention strategies. The EAC connects patients quickly and efficiently with a rheumatologist who can evaluate joint pain and start an appropriate course of treatment. The patient’s primary care physician is kept fully advised of findings and recommendations. The Gosden Robinson Early Arthritis Center is located at Hospital for Special Surgery at 535 East 70th Street in Manhattan.
About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 3 in rheumatology by U.S. News & World Report (2017-2018), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. HSS has locations in New York, New Jersey and Connecticut.